Illumina Inc is a leading biotechnology company that specializes in the development and manufacturing of advanced genomic sequencing technologies. The company focuses on providing innovative solutions for researchers and healthcare professionals, enabling them to analyze DNA, RNA, and other genomic materials with high accuracy and efficiency. Illumina’s cutting-edge sequencing platforms and reagents support a wide range of applications, including genomics research, clinical diagnostics, and personalized medicine, thereby playing a crucial role in advancing the field of genomics and improving human health. Read More
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 22.4% in the afternoon session after it reported third-quarter 2025 financial results that beat profit expectations and raised its full-year guidance. Illumina announced non-GAAP earnings of $1.34 per share, which was well above analyst estimates of $1.17. While revenue for the quarter remained flat year on year at $1.08 billion, it also surpassed expectations. The positive market reaction was largely fueled by the company's improved forecast. Management raised its full-year adjusted earnings per share guidance to a midpoint of $4.70, a 4.4% increase from its previous outlook.
Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates.
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates.
As of October 2025, Nvidia (NASDAQ: NVDA) stands on the precipice of a historic $5 trillion market valuation, a testament to its unparalleled dominance in the artificial intelligence (AI) and high-performance computing (HPC) sectors. This monumental achievement, which has seen its market capitalization soar past $4.5 trillion and, at
Illumina (ILMN) presents a strong value investment case with attractive valuation, high profitability, and solid financial health, trading below industry peers.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.3% in the afternoon session after an analyst at Barclays maintained a cautious "Underweight" rating on the company.
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic move marks a significant pivot for the genomic sequencing giant, as it ventures deeper into the burgeoning fields
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent strategic developments. This significant uptick reflects investor confidence in the life sciences giant's aggressive expansion into high-growth sectors,
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the afternoon session after the company announced the launch of BioInsight, a new business unit designed to accelerate drug discovery using artificial intelligence. The new venture aims to help researchers and pharmaceutical companies analyze and interpret vast amounts of complex biological data, known as multiomic data. By combining its strengths in genetic sequencing, software, and AI, Illumina's BioInsight unit will provide solutions to identify new drug targets, understand biological pathways, and uncover disease mechanisms. This strategic move is intended to meet growing industry demand for data-driven insights, supporting the company's long-term growth by expanding its role in the life sciences and healthcare sectors.
San Francisco, CA – September 30, 2025 – Nvidia Corporation (NASDAQ: NVDA) continues its unprecedented ascent, cementing its position as the undisputed titan of the artificial intelligence (AI) era. As of late September 2025, the company's robust financial performance and relentless innovation in AI hardware and software are not only driving its
